ACE Report Cover
Single-shot dose and continuous infusion of TXA have similar efficacy in primary TKA
Language
Download
Cite
+ Favorites
Language
Download
Cite
+ Favorites
AceReport Image
ARTHROPLASTY
Single-shot dose and continuous infusion of TXA have similar efficacy in primary TKA .
Verified
This report has been verified by one or more authors of the original publication.

Single dose intravenous tranexamic acid as effective as continuous infusion in primary total knee arthroplasty: a randomised clinical trial

Arch Orthop Trauma Surg. 2015 Apr;135(4):465-71
Contributing Authors

H Hourlier N Reina P Fennema

106 patients undergoing total knee arthroplasty were randomized to receive either a 30mg/kg bolus dose of tranexamic acid (TXA), or 10mg/kg dose TXA plus 2mg/kg/h continuous infusion postoperatively for 20 hours. The purpose of this study was to compare blood loss within the first week of surgery, as well as complications and clinical outcomes within the first year of surgery. The findings illustrated no significant differences between groups for any of the measured outcomes. Additionally, no venous thromboembolic events were noted in any patient of either group.

Unlock the Full ACE Report

You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or upgrade today and gain access to all OrthoEvidence
content for as little as $1.99 per week.
0 of 4 monthly FREE articles unlocked
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time.
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Translate ACE Report

OrthoEvidence utilizes a third-party translation service to make content accessible in multiple languages. Please note that while every effort is made to ensure accuracy, translations may not always be perfect.

Cite this ACE Report

OrthoEvidence. Single-shot dose and continuous infusion of TXA have similar efficacy in primary TKA. ACE Report. 2015;4(6):5. Available from: https://myorthoevidence.com/AceReport/Show/single-shot-dose-and-continuous-infusion-of-txa-have-similar-efficacy-in-primary-tka

Copy Citation
Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Premium Member Feature

To access this feature, you must be logged into a premium OrthoEvidence account.

Share this ACE Report